Frederick Appelbaum, MD

Frederick Appelbaum, MD

Executive Vice President and Deputy Director, External Affairs
Fred Hutchinson Cancer Research Center
Professor, Division of Medical Oncology
University of Washington


M.D., Tufts University, 1972
A.B. (cum laude), Dartmouth College, 1968

Leadership Focus

As deputy director Appelbaum leads Fred Hutch’s strategic research partnerships with the National Institutes of Health and other federal agencies. He also represents the institution to the world at large, developing community relationships and programs needed to sustain the Hutch’s continued growth and impact. Another major focus of Appelbaum’s role is maintaining the fiscal health of Fred Hutch through sustained federal funding and other revenue sources, including philanthropy and technology transfer.

Appelbaum’s responsibilities also include ensuring that the Hutch’s clinical research advances are effectively shared with the medical community, particularly in the area of cutting-edge cancer diagnostic tools that help inform the best treatment based on the genetic and molecular characteristics cancer.

Research Interests

Appelbaum’s research focuses on the biology and treatment of leukemias, lymphomas and other blood cancers. He was the lead author of the first paper to describe the successful use of autologous bone marrow transplantation, a therapy now used in more than 30,000 patients annually. He was also a key contributor to the discovery and development of gemtuzumab ozogamicin, known commercially as Mylotarg, the first monoclonal antibody approved by the Food and Drug Administration to treat acute myeloid leukemia.

Related News


Contact Information

(206) 667-4412
(206) 667-6936
Additional contact

Mailstop: D5-310